[Research progress of mesenchymal stem cells in the treatment of medication-related osteonecrosis of the jaw].

Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication characterized primarily by jawbone necrosis, induced by bisphosphonates or other targeted agents for systemic diseases. With the advancement of systemic anticancer therapies, the survival of patients with advanced malignancies has been prolonged, leading to an annual increase in the number of patients with MRONJ. However, there is currently no effective treatment for MRONJ worldwide. Recent studies have indicated that mesenchymal stem cells exhibit significant potential for osteogenic and angiogenic differentiation, proliferation, immunomodulation, and anti-inflammatory effects, thereby providing a novel therapeutic strategy for medication-related osteonecrosis of the jaw. This article reviews the research on mesenchymal stem cell therapy for MRONJ, providing a reference for its clinical research and treatment.